152 related articles for article (PubMed ID: 9135499)
1. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y
Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499
[TBL] [Abstract][Full Text] [Related]
2. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
3. Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
Moreland N; Finlay GJ; Dragunow M; Holdaway KM; Baguley BC
Eur J Cancer; 1997 Sep; 33(10):1668-76. PubMed ID: 9389932
[TBL] [Abstract][Full Text] [Related]
4. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
Leontiou C; Lakey JH; Austin CA
Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
[TBL] [Abstract][Full Text] [Related]
5. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
6. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Finlay GJ; Riou JF; Baguley BC
Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
9. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
Finlay GJ; Holdaway KM; Baguley BC
Cancer Chemother Pharmacol; 1994; 34(2):159-65. PubMed ID: 8194167
[TBL] [Abstract][Full Text] [Related]
10. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
11. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
12. Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy.
Chourpa I; Morjani H; Riou JF; Manfait M
FEBS Lett; 1996 Nov; 397(1):61-4. PubMed ID: 8941714
[TBL] [Abstract][Full Text] [Related]
13. Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta.
Marsh KL; Willmore E; Tinelli S; Cornarotti M; Meczes EL; Capranico G; Fisher LM; Austin CA
Biochem Pharmacol; 1996 Dec; 52(11):1675-85. PubMed ID: 8986129
[TBL] [Abstract][Full Text] [Related]
14. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
15. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
[TBL] [Abstract][Full Text] [Related]
16. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
18. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
19. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
Gromova II; Thomsen B; Razin SV
Proc Natl Acad Sci U S A; 1995 Jan; 92(1):102-6. PubMed ID: 7816796
[TBL] [Abstract][Full Text] [Related]
20. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Schneider E; Darkin SJ; Lawson PA; Ching LM; Ralph RK; Baguley BC
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1783-90. PubMed ID: 2850193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]